"Me Too" Drugs
› Now Your Liver Doesn't Have to Make It For You
› How Many PPIs Does the World Need?
› Bad Luck For Novartis - And For Diabetics
› Godzilla vs. Mothra? Relman vs. Epstein!
› By a Nose in a Head to Head
› No Clear Winners
› Gritting Our Teeth
› An Economist Who Gets It
› Alex Tabarrok on Me-Too Drugs
› Blurry Copies
› The Last Word (For A While) On Me-Too Drugs
› Me Too, Part Two
› Clinical Trials And What to Do With Them
› Hypertension and Marketing
› Merck and Its Competition
› Our Buddies at the FDA
› Adam Smith Goes Pharmaceutical
› Innovation and Its Discontents
› Claritin and Clarinex

Academia (vs. Industry)
› Lowe's Law of Diurnal Distribution
› Getting To Lyrica
› Scrape Off Some Attitude
› Ugly, But Useful
› Drugs From Where?
› The Doctorate and Its Discontents
› Naked Synthesis
› What Can Academia Do?
› Problems and Solutions
› Peter Kim, So Far
› Not On the Same Page
› University of Drug Discovery?
› The Great Divide
› Mutual Suspicions
› Differences Between Academia and Industry, Pt. 4
› Sneaking Out for an Interview
› Getting A Job
› More on Question Four
› Getting a Faster PhD?
› The Bones of the World
› Don't Become A Scientist?
› Like Moving Furniture Across a Tightrope
› Gumming Up the Amyloid Works
› The NIH in the Clinic
› One More On Basic Research and the Clinic
› A Real-World Can O' Worms
› How Much Basic Research?
› How It Really Works
› Will the Uncommon Work for the Common Good?
› Industry vs. Academia: The Mental Aspect
› Stuart Schreiber on Stuart Schreiber
› Differences Between Academia and Industry, Pt. 2
› Differences Between Industry and Academia, Pt. 1
› On the Money

Aging and Lifespan
› Resveratrol in Mice
› Why Buy, Anyway?
› $720 Million Worth of Sirtuin Research
› Breaking the Contract of Aging
› More Sirtuins With More Effects
› And Thee, O Time
› Sir2 Surprise
› Klotho: Sooner Than You Think?
› Breathing and Aging
› When Natural Selection's Through With You - Part II
› After Natural Selection's Through With You

Alzheimer's Disease
› Rember for Alzheimer's: Methylene Blue's Comeback
› Bapineuzumab: Good For Anything or Not?
› Patents Stopping an Alzheimer's Wonder Drug?
› Another Alzheimer's Compound Goes Down
› Protecting Amyloid's Parent?
› Elan Tries Again
› In Which I Hate A Wonder Drug
› Alzheimer's: A Report From the Front
› ApoE4: Test or Not?
› Fast Plaques in a Slow Disease
› Checking The Numbers on the Alzheimer's Test
› Beta-Secretase: Not So Fast?
› Failure: Not Your Friend, But Definitely Your Companion
› How Good Is Aricept, Anyway?
› A Trial Too Far
› Gumming Up the Amyloid Works
› Silent Mutations and Noisy Ones
› Back on the Air
› Alzheimer's Vaccine Refuses to Die
› Sleeping Dragons
› Maybe They Can Formulate It in Madelaines
› Who Dares, Wins?
› Modeling the Brain?

Analytical Chemistry
› Start Small, Start Right
› These Fragments I Have Shored Against My Ruins
› Mass Spec on Mars
› Floyd Landis: Could His Cortisone Treatments Exonerate Him?
› Testosterone, Carbon Isotopes, and Floyd Landis
› Doublets, Triplets, Whateverlets
› Medicine Man

Animal Testing
› Whose Guess Is Better?
› The Animal Testing Hierarchy
› Unacceptable
› Less Than Zero
› Worst Animal Model: Nominations Are Open
› Formally Undecideable
› Rats Rule, Right?
› Ends, Means, Rats, and Dogs
› Model Systems, From Inside and Out
› Furry Judges, With Tails
› What to Do When the Rats Die on You
› Rats, For Fear of Worse
› You'll Only Get Answers
› Modeling the Brain?

Autism
› Thimerosal. Again.
› Thimerosal, Again
› A Mechanism for Thimerosal
› Here and There
› Compare and Contrast
› The Rate of Autism
› Clearance Sale
› Thimerosal - A Chemical Point
› Thimerosal - a Chemical Point
› Clearance Sale
› A Quick Tour Through the Mudhole
› More on Autism (And Mercury)
› More on Autism and Mercury
› A Quick Tour Through the Mudhole
› Neurotoxins
› Neurotoxins
› Doing Justice to Thimerosal, And the Story
› Doing Justice to Thimerosal, and the Story

Biological News
› Receptors: Can't Live With 'Em, Can't Understand 'Em
› Killing Proteins Wholesale
› Empty As Can Be
› Nanotech Stem Cells, Order Now!
› RNA Interference: Even Trickier Than You Thought
› Getting Real With Real Cells
› Rainbows and Fishing Expeditions
› Avandia: Going Under for the Third Time?
› A Real Genetic Headscratcher
› What We Don't Know About Enzymes
› Checking The Numbers on the Alzheimer's Test
› Let Us Now Turn To the Example of Yo' Mama
› More Things Than Are Dreamt Of
› Visfatin: Real Or Not?
› It Went Up Instead of Down
› Peptides as Texts
› Neowater Replies
› Nanotech Wonder Water?
› Stem Cell Disaster
› Grand Rounds Today, and Next Week
› RNAi: The Awkward Age
› Kinases and Their Komplications
› The Vapor Trail I Referred To
› It's a Bacterial Planet, You Know
› There'd Better Not Be an Argon Receptor
› All Bets Are Now Officially Off
› A New Cancer Target - Maybe
› Proteinocentrism
› Gene Therapy Decisions

Birth of an Idea
› Vial Thirty-Three, And More
› Back on the Air
› Vial Thirty-Three: Warp Drive
› The Race Is On
› Publish, Then Perish
› The Horse Latitudes
› Good News, Now That I Think About It!
› Back To Life
› Vial Thirty-Three: The Third Run
› Vial Thirty-Three Rides Again
› Vial Thirty-Three: One Up, One Down
› Mid-day Update
› Minute by Minute
› Vial Number Thirty-Three
› Cliff Diving
› A Scientist's Resolutions
› Report From What I Think is the Frontier
› Experimental News
› News Flash: I May Not Be a Fool
› Data, At Last
› Experimental Update
› Experimental Update, For Those Who Care
› Live The Stereotype!
› The Consolations of Pure Research
› Don't Talk To Yourself So Much
› Mismatched Socks
› A Little Ambiguity Would Be Welcome Right About Now
› Dr. Lowe? I Have Your Hypothesis on Line Two
› If This Doesn't Work, There's Only Reality To Fall Back On
› Good News, Backing Slowly Through the Door?
› Waiting for the Metaphorical Phone to Ring
› Per Fits and Starts, Ad Astra
› Here It Goes
› Nature Stood Me Up
› Close to the Vest
› Close To the Vest
› Experimental Update
› In Case Anyone's Wondering
› Back for More
› Meanwhile, Back at the Chocolate Factory
› The Nuts and Bolts of a New Idea
› Measure Twice, Cut Once

Blink ›
› Nature Doesn't Care: Latest in a Series
› Vaccines by the Dozen
› Follow Which Money Where?
› An Experiment in Progress?
› Alex Tabarrok on Me-Too Drugs

Blog Housekeeping
› Back
› Time Off
› Happy Fourth of July
› Leaving Comments: A Fix
› Explaining It All
› Quick Note
› Anonymity?
› Day Off
› Commenting Issues
› Back On the Air
› Snow Day
› Synthetic Prep of the Day: Chocolate Pecan Pie
› Holiday Break
› Bright Lights and Applause?
› Blogroll Update
› Meet the Blogger?
› Not Necessarily So
› Two Weeks Off
› Real Life, Which Costs Real Money
› But Enough About You
› Blogroll Update
› Linkage!
› Back From DC
› You Want Me to Just Talk? No Problem.
› Comments on Comments
› Blogroll Update
› Back on the Air
› Work At Home! It's Easy; It's Fun!
› Holiday Schedule
› Shameless Self-Promotion
› Elsewhere
› Watch This Space
› Links and Such
› Darn Photons
› Here and There
› A Friday Linkfest
› Back on the Air
› Travel
› Linkorama
› Missed One!
› A Lengthy Day
› Technical Difficulties
› Blogroll Revamp
› Various Updates
› Comments Welcome - Really
› Instead of Working
› Procrastination Assistance
› Outside Reading, and Plenty of It
› And Another Thing. . .
› Blogging About Science Blogging
› Even More Worthwhile Stuff
› Like, Er, Fine Wine. I Hope.
› Summer Hours
› Continued Slacking
› Outside Reading
› New Address
› One Problem Solved, Anyway
› A Technical Question
› And Now A Word. . .
› Schedule Update
› Holiday Blogging
› Stocking Stuffers, of a Sort
› Now With The Great Taste of Fish
› Comment Problems
› Two Days Off (From This, Anyway)
› No Coming Attractions Here
› A Question For the Audience
› Summer Hours
› The Last Word on Taste
› Categories
› Welcome Back!
› Catching Up
› Here and There

Business and Markets
› RNAi: Bubble or Not?
› Genentech and Roche, Act Two
› Roche Palo Alto: What's Going On?
› Job Seekers: Genentech, GSK, and Elsewhere
› GSK Layoffs: Yes, Again
› Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
› Should Genentech Be a Part of Roche?
› Vytorin: Another Round of Nasty Results
› Sharing the Enlightenment
› More on Outsourcing
› Pfizer's Prospects: Just Ducky
› Alli: "Underwhelming"
› Suits vs. Lab Coats?
› More On the GSK Layoffs
› GSK: Money-Green Outside, Pink-Slip Inside
› A Breath of Fresh Air from Fuji
› Nullius in Verba
› Awash in Yen
› Cordaptive Q and A
› Why Buy, Anyway?
› $720 Million Worth of Sirtuin Research
› Free Sushi in the Cafeteria!
› A Solution, Courtesy of the MIT Faculty
› Hits, Misses, and Some More Misses
› How Many PPIs Does the World Need?
› Drugs and Money
› Laissez-Faire?
› Cheap Happiness
› Drugs and Money and How It Feels
› Dollar, Drugs, and Advertising
› Top of the Heap
› Hearing Footsteps
› Biogen's Not For Buying. For Now.
› Med-Chem Layoffs, On the Front Page
› More Belts Tighten
› How You Doin'? How's Everybody Doin'?
› Lights, Camera, Pharma!
› Come On. Improve, Already.
› Surveying the Exubera Crater
› Biogen on the Block?
› More Layoffs, And What They Might Mean
› Hey, Graduates! Negotiate Hard, You Hear, Now?
› Good News From the HR Department!
› Have We Got A Deal For You!
› Guess That Market
› Oh, Come On
› Ah, Rumors
› Buying What You Can't Make? Or What?
› Exubera Spirals Toward the Drainpipe
› European Drugs, American Drugs
› Knowing What You Know. . .
› Alas, Dendreon
› Outsourcing Blues?
› Put Your Money Down
› Layoffs - Again
› Amgen: The Pythian Oracle Laughs Again
› Buy! Sell! Shout! Moan!
› Vaccines Everywhere
› Vectibix Lurches A Bit
› Schering-Plough Goes Shopping
› Biotech's Net Loss?
› A Good Day's Work
› Good Sense Breaks Out, Film at Eleven?
› BMY-SNY?
› The Big Picture
› Pfizer's Pfinances
› Novo Nordisk Axes Med-Chem
› ICOS In Pieces?
› Pfizer's Sizing
› Sell! (It's Not Just Me)
› Help Wanted - I Hope
› Chinese Med-Chem - In China, For Once
› Hope, Springing Eternal And All That
› You Can't Make Money If You Don't Get Paid
› Blow The Trumpets
› Up Periscope And Fire All Bow Tubes
› Imclone, Drama Queen of Biotech
› Tough Targets
› Walking the Plank at Bristol-Myers Squibb
› Merck: Unfigure-outable
› The Great Plavix Disaster
› Pfizer's Man at the Top
› Pfizer Recalculates
› The Sun Shines at Pfizer
› Getting and Spending
› J&J Shrinks Their Labs Again
› Neurocrine's Choice
› The Fur Continues to Fly
› What's German For "Food Fight"?
› Leadership Secrets of the Data Fudgers
› Full Disclosure
› Golden Parachute, Still Packed and Ready
› Rioting for Unemployment
› Can You Say "Uebernahmeangebot"?
› Nitromed's Slow Decline
› More on Outsourcing
› J&J Shakes Things Up
› Forecast: Rain, Eventually
› Imclone Revisited
› The Tar Pit Beckons
› James Cramer, Biocryst, and You
› Human Genome Science Hits the Wall
› Where Do the Good Ones Go?
› The Check Shows Up in the Mail. Really.
› Pfizer Opens Their Wallet - Again
› You Figure It Out
› Public Utility, You Say?
› Punching the Clock at Merck
› What Ails the Germans?
› The Globalization of Med-Chem
› Drug versus Stock
› Waiting for the FDA
› Glaxo v. Pfizer: Sales Force Stand-Down?
› Pfizer's Prospects
› Maybe They Should Fire Them All?
› Optioning the Drug Portfolio
› Don't Ask; Just Trade
› Let's See What the Sharks Think of These Steaks!
› Could I Have a Side Order of Risk With That?
› Public Utility, You Say?
› How Bad Are the Cox-2 Inhibitors, Anyway?
› A Day With All the Bark Left On It
› Rank and Yank?
› Measure for Mismeasure
› Around and About
› Another Shot Across the Bow
› Vox Populi
› As Goes ASCO. . .
› A Capacious Rat-Hole Indeed
› Deferred Gratification Is Better Than None At All
› Yahoots
› Foaming Up Over the Edge
› Bulking Up
› Thou Hast It Now. . .
› Play It Again
› Tasty New Recipes for the Root of All Evil
› Quis custodiet ipsos custodes?
› Pravachol vs. Lipitor Update
› Mismatched Socks
› Ignorance Was Bliss
› I will do such things - What they are yet I know not. . .
› Allons Pharmas de la Patrie!
› . . .Your Huddled Pharmas Yearning to Breath Free
› Ah, Marketing
› Mismeasure for Mismeasure
› Measure for Measure
› What Sort of Number Did You Have in Mind?
› O Brave New Market, That Has Such Medicines In It
› Bad News at a Bad Hour of the Night
› Caveat Lector
› Muddying the Water For Fun and Profit
› Back For Some More
› Marketing Ueber Alles
› By Any Other Name
› The Apatosaurus. The Spruce Goose. The Pyramids
› The Irish Elk. The Mongol Empire. And Other Things That Got Too Big to Work Well.
› A Less-Than-Subtle Plan

Cancer
› GSK Layoffs: Yes, Again
› Vytorin: Another Round of Nasty Results
› Auroral Activity
› And You Thought Exubera Was A Disaster Before
› Whose Guess Is Better?
› Judah Folkman
› Plants For Cancer?
› Bacterial Infection: Better Or Worse Than Cancer?
› Arsenic, Patents, and the World
› The Current Cancer Long-Jump Record
› Phase Zero?
› Let A Thousand Flowers Bloom
› Amgen: The Pythian Oracle Laughs Again
› Awful, No Doubt. But Not As Awful as Before?
› Vaccines Everywhere
› Failure: Not Your Friend, But Definitely Your Companion
› Vectibix Lurches A Bit
› A Good Day's Work
› Good Mistakes?
› An Innocent Question
› Reality, Here In This Little Dish
› Sell! (It's Not Just Me)
› Blow The Trumpets
› Here and There
› Imclone, Drama Queen of Biotech
› Tell 'Em You Work On Something Else
› Resistance Isn't Quite Futile
› That Fount of Information We Call ASCO
› Jungle Rot
› New Frontiers in Self-Deception
› Price Gouging or Not?
› Gold and Lasers
› What's It Worth to You?
› Mice, Humans, and Cancer
› Another Shot at Cancer
› The Hard News on Cancer
› Hype or Hope?
› No Such Disease
› Selectivity: One of Those Flexible Concepts
› A Tale of Two Trials
› Cancer Delusions
› When the Alternative is Nothing
› Biotech At Last, Eh?
› That Has to Be Good, Right?
› ASCO Fever
› 'Tis the Season
› The Price of Desperation
› Targretin's Troubles
› Drug versus Stock
› Still Not All That Easy
› Springtime for Oncology
› What We Are Pleased to Call State of the Art
› Black Friday: One Damn Thing After Another
› The Coming Oncology
› Check, Please
› Tarceva Targets
› Clay Lies Still, But Blood's A Rover
› Costs and Benefits, Risks and Rewards
› Another Shot Across the Bow
› Bungee Jumping with PPAR Drugs
› It'll Cost You
› Vox Populi
› As Goes ASCO. . .
› All the Myriad Ways
› Deferred Gratification Is Better Than None At All
› Yahoots
› Foaming Up Over the Edge
› A New Cancer Target - Maybe
› Back on the Air
› Pneumonia, of All Things
› O Brave New Market, That Has Such Medicines In It
› Not Even Funny
› Genetic Optimism
› The Wall Street Journal versus the FDA
› Consequences of Aneuploidy
› Aneuploidy, or What're A Few Chromosomes, More or Less?
› HER-1 And HER-2, Too
› Save Your Tears
› A Few Words
› Did He Say What They Thought He Said?
› Now Is the Peptide of Our Discontent
› Hype and Glory
› More Imclone, More Food for Thought
› A Certain Tension in the Air
› Imclone in Progress

Cardiovascular Disease
› Vytorin: Another Round of Nasty Results
› Prasugrel: Come Back This Fall
› Merck, Vioxx: Seventeen and Three
› In Which I Hate A Wonder Drug
› Cordaptive Q and A
› Another Cholesterol Medication Goes Down (Or Does It)?
› Whose Guess Is Better?
› Vytorin Numbers
› Vytorin: It's A Pity
› Pfizer vs. the NEJM: A Legal Showdown
› Off Target? Which Target Did You Mean?
› A Look Under the Hood
› Vytorin, Holed Under the Waterline
› Renin, Wherefore Art Thou, Renin?
› Rimonabant, Out In the Light
› The Avandia Wars Continue
› More Avandia, And More on Marketing
› Avandia: Trouble or Not?
› The HDL Compost Pile
› AGI-1067: Dead or Alive?
› Torcetrapib: The Foil-Lined Hat Perspective
› Bigger And Greasier
› Too Near the Sun?
› The Torcetrapib Catastrophe
› Pfizer's Sizing
› Ah, the Heck With the Error Bars
› Elsewhere
› It Should Work. It Just Doesn't.
› Plavix Plot Twists
› Merck: Unfigure-outable
› The Great Plavix Disaster
› Pfizer Recalculates
› More Statin Skirmishing
› Vioxx: 18 Months to Trouble?
› As Merck Caroms Off Another Tree
› Merck and the Numbers
› Merck's Latest Underwhelming Data
› The New England Journal And Its PR Flacks
› Merck, So Far
› Nitromed's Slow Decline
› The Big Statin Pillow Fight
› NEJM vs. Its Contributors, Round Two
› Merck versus the New England Journal
› Does Celebrex Have A Future At All?
› An Expensive Way Back for Celebrex
› The New England Journal of Legal Immunity?
› Selectivity: One of Those Flexible Concepts
› Merck on Trial
› Where's the Combo?
› A Drug's Target, Finally
› COX-2 Aftermath
› Waiting for the FDA
› Boarding Up the Windows
› The FDA Weighs In
› Let's See What the Sharks Think of These Steaks!
› Cox-2 Confusion
› How Bad Are the Cox-2 Inhibitors, Anyway?
› More on Merck
› A Day With All the Bark Left On It
› The Last Word (For A While) On Me-Too Drugs
› Me Too, Part Two
› Clinical Trials And What to Do With Them
› Pravachol vs. Lipitor Update
› Ignorance Was Bliss
› Ezetimibe, The Press, and More
› The Beginning? It's Right Past the End. . .
› Sic Transit Gloria Mundi
› Trials of Trials
› Cholesterol Lowering, One Way or Another

Chem/Bio Warfare
› The Litvinenko Case: More On Polonium and Alpha Particles
› Evil Thoughts of Evil Things
› A Fire, And Its Flames
› Osmium Tetroxide, Of All Things
› Ricin Redux
› More Ricin
› Ricin
› And While We're On the Subject - Mercury?
› A Mystery Gas?
› Chemical Warfare, Part Five: The Real World
› Chemical Warfare, Part Four: More On Nerve Agents and Their Chemistry
› Chemical Warfare, Part Three: How Nerve Agents Work
› Chemical Warfare, Part Two: Lethal Agents (Other Than Nerve Gas)
› Chemical Warfare, Part One: Introduction

Chemical News
› An Impressive Nanolist of Nanocitations
› Copper: A Gentleman's Disagreement
› New Tricks With Glassware
› DNA Forklifts, DNA Pliers
› Le Dernier Cri
› One For the Brave
› Ertl Wins: Down With Witchcraft
› All Sorts of Holes
› Steve Ley, Azadirachtin, and Me (Very Much in That Order)
› ACS Meetings
› Calcium: A Backwater
› Smell the Vibrations
› Six Chem-Geek Questions
› Hexacyclinol Rides Again
› Hexacyclinol? Or Not?
› Chem-Geek Alternate History
› A New Route to Tamiflu?
› More on Woodward
› Archaeologists Announce Dirty Laundry Discovery
› Why Total Synthesis?
› Climbing Mountains

Clinical Trials
› Rember for Alzheimer's: Methylene Blue's Comeback
› Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
› Vytorin: Another Round of Nasty Results
› Glaxo Asks the Eurocrats
› Another Alzheimer's Compound Goes Down
› Fun With Bacteria
› And You Thought Exubera Was A Disaster Before
› Another Cholesterol Medication Goes Down (Or Does It)?
› Vytorin: It's A Pity
› You Get What You Pay For?
› Taranabant in Trouble?
› Hits, Misses, and Some More Misses
› Antidepressants: Depressing News or Not?
› A Look Under the Hood
› Vytorin, Holed Under the Waterline
› Come On. Improve, Already.
› Deactivation, After All
› Rimonabant: Down to Earth
› Rimonabant, Out In the Light
› Phase Zero?
› Pecunia Non Olet?
› The Avandia Wars Continue
› Knowing What You Know. . .
› Avandia: Trouble or Not?
› Deep Breaths
› Vectibix Lurches A Bit
› FDA Advisory Panels: Pay, No Play
› AGI-1067: Dead or Alive?
› Vertex, Hepatitis, and Gripping the Arms of Your Chair
› Upside Down Activity
› Torcetrapib: The Foil-Lined Hat Perspective
› Too Near the Sun?
› The Torcetrapib Catastrophe
› It Should Work. It Just Doesn't.
› A Spray-Painted Crystal Ball
› Tough Targets
› Tegenero, In Detail
› Vioxx: 18 Months to Trouble?
› Formally Undecideable
› A Question For the Crowd
› Access to Phase I Drugs: A Constitutional Right?
› A Word to the Wise About TGN1412
› TNG1412: Was There a Warning?
› Update on TGN1412
› No Immunity From Immunity
› But His Name Lives On. . .
› The FDA Loosens Its Tie
› An Expensive Way Back for Celebrex
› Rigel's Puzzling Failure
› This Had Better Be Good
› By a Nose in a Head to Head
› No Clear Winners
› Muraglitazar's Turn
› Gritting Our Teeth
› Where's the Combo?
› Still Not All That Easy
› The NIH in the Clinic
› One More On Basic Research and the Clinic
› How It Really Works
› Unburied
› Me Too, Part Two
› Clinical Trials And What to Do With Them
› Fast, Cheap, and Sometimes Even Good
› Primum Non Nocere, Eh?
› The Journals Fight Back
› Your One-Stop Clinical Data Superstore?
› Cue the Music
› Pravachol vs. Lipitor Update
› Ignorance Was Bliss
› More From the Me-Too Front
› Putting A Price on Proving It
› Here and There
› Trials of Trials
› Statins and Multiple Sclerosis
› Muddying the Water For Fun and Profit
› Save Your Tears

Closing Time
› Med-Chem Layoffs, On the Front Page
› Massachusetts Moving
› A Post I've Been Looking Forward to For Months
› Layoffs - Again
› More Help Wanted?
› Have We Got a Job For You!
› A Break, Whether I Felt Like It Or Not
› Open For Business
› Ghost Town
› Out With the Old
› Cleans Down to What Should Be the Shine
› Hi, My Name Is [...]
› The Paper Mountain
› Vial Thirty-Three: Warp Drive
› Where Do All The Chemicals Go?
› The Race Is On

Current Events
› More Pfizer Layoffs?
› Nullius in Verba
› Judah Folkman
› Ah, Politics
› Unnatural, And Proud Of It
› Ertl Wins: Down With Witchcraft
› Nobel Chemistry Odds
› Nobel Season
› The Choir Hears It Again
› Pour Encourager Les Autres
› Access To Science
› Time To Conduct Some Business
› Layoffs - Again
› Hedgehogs in Stockholm
› F. A. Cotton, 1930-2007
› CMPI Conference: Critical Path
› CMPI Conference: Lunch With the FDA
› CMPI Conference: Panel on the Politics of Drug Evaluation
› CMPI Conference: Panel on Media Coverage
› That Smell
› And The Winner Is. . .
› Injustice
› The Litvinenko Case: More On Polonium and Alpha Particles
› Polonium Poisoning
› Help Wanted - I Hope
› Here and There
› Floyd Landis: Could His Cortisone Treatments Exonerate Him?
› Airplanes and Chemicals
› Testosterone, Carbon Isotopes, and Floyd Landis
› Explosion News
› Poor Put-Upon Intelligent Design
› The Dover Decision Comes Down
› Merck Update
› Merck, Finally
› Intelligent Design, Molecule By Molecule
› The Dover Decision
› Merck Off the Mat
› Metathesis Nobel!
› A Piece of the Action
› Okay, One More Merck Point
› No More Merck For A Couple of Days
› Judgement Day
› Welcome to the World, I Hope
› Strangers on a Train
› Special Off-Topic Weekend Irrelevancy
› Actually, It's Everything Else That's Off-Topic
› Happy Fourth of July
› Osmium Tetroxide, Of All Things
› And Another Thing. . .

Diabetes and Obesity
› Metabolic Hope Springs Eternal
› All The Fat Cells You'll Ever Have - Sort Of
› Alli: "Underwhelming"
› Merck Bails on Natural Products
› Why Buy, Anyway?
› Exubera, Safety, and No Guarantees
› And You Thought Exubera Was A Disaster Before
› Whose Guess Is Better?
› Taranabant in Trouble?
› Off Target? Which Target Did You Mean?
› More On Merck and Taranabant
› What You Become Known For
› Eat It, Breath It, Soak in It?
› Avandia: Going Under for the Third Time?
› Bad Luck For Novartis - And For Diabetics
› Depressing Figures for Acomplia
› Surveying the Exubera Crater
› More Things Than Are Dreamt Of
› Buying What You Can't Make? Or What?
› Exubera Spirals Toward the Drainpipe
› Deactivation, After All
› Visfatin: Real Or Not?
› Right Down the Alli
› Rimonabant: Down to Earth
› Rimonabant, Out In the Light
› The Avandia Wars Continue
› More Avandia, And More on Marketing
› Avandia: Trouble or Not?
› Exubera: This Time With Feeling
› Rimonabant, Slowly
› You Can't Make Money If You Don't Get Paid
› Up Periscope And Fire All Bow Tubes
› The Inscrutable French
› Neuropeptide Y Dies, But It Never Surrenders
› Tell 'Em You Work On Something Else
› Rimonabant Arrives
› What's French for "Trust Us"?
› Rimonabant Bangs Into. . .Something
› Pfizer Takes a Deep Breath
› Ghrelin and Obestatin
› Pargluva Goes Down?
› This Had Better Be Good
› Waiting for Pargluva
› Muraglitazar's Turn
› Gritting Our Teeth
› Symlin, At Last
› Worries about Rimonabant?
› Bungee Jumping with PPAR Drugs
› Why Own the Car, When You Can Own the Road?
› Ah, Marketing
› Of All Sad Words. . .
› Fighting City Hall
› A Treadmill Pill?
› Enzymes, Right and Wrong

Drug Assays
› Receptors: Can't Live With 'Em, Can't Understand 'Em
› Sharing the Enlightenment
› Oops
› The Miracle Solvent
› Whose Guess Is Better?
› Start Small, Start Right
›